{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:30:06Z","timestamp":1793608206961,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:24:25Z","timestamp":1775690665000},"page":"e730-e739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?"],"prefix":"10.1016","volume":"26","author":[{"given":"Megan","family":"Metzger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clml.2026.04.002_bib0001","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.04.002_bib0002","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.04.002_bib0003","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of Ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.04.002_bib0004","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.04.002_bib0005","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.002_bib0006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.04.002_bib0007","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00277-021-04682-x","article-title":"Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval","volume":"101","author":"Verstovsek","year":"2022","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1016\/j.clml.2026.04.002_bib0008","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V122.21.393.393","article-title":"Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor Fedratinib (SAR302503) in patients with myelofibrosis (MF)","volume":"122","author":"Pardanani","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.04.002_bib0009","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"34","key":"10.1016\/j.clml.2026.04.002_bib0010","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10373","key":"10.1016\/j.clml.2026.04.002_bib0011","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2026.04.002_bib0012","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.clml.2026.04.002_bib0013","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.04.002_bib0014","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2007.1.346","article-title":"Biology and treatment of primary myelofibrosis","volume":"2007","author":"Hoffman","year":"2007","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.clml.2026.04.002_bib0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.hoc.2020.12.003","article-title":"Current clinical investigations in myelofibrosis","volume":"35","author":"Venugopal","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"10.1016\/j.clml.2026.04.002_bib0016","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/cells10051034","article-title":"Next generation therapeutics for the treatment of myelofibrosis","volume":"10","author":"Tremblay","year":"2021","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.clml.2026.04.002_bib0017","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2026.04.002_bib0018","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.clml.2026.04.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100056","article-title":"Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response","volume":"2","author":"Pemmaraju","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"6","key":"10.1016\/j.clml.2026.04.002_bib0020","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study","volume":"9","author":"Pemmaraju","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.04.002_bib0021","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.HS9.0000843680.94912.c5","article-title":"S197: navitoclax plus ruxolitinib in jak inhibitor-na\u00efve patients with myelofibrosis: preliminary safety and efficacy in a multicenter, open-label phase 2 study","volume":"6","author":"Passamonti","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2026.04.002_bib0022","series-title":"Presented at: The 65th American Society of Hematology Annual Meeting and Exposition; December 10","article-title":"Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis","author":"Pemmaraju","year":"2023"},{"issue":"1","key":"10.1016\/j.clml.2026.04.002_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"issue":"32","key":"10.1016\/j.clml.2026.04.002_bib0024","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-na\u00efve myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.04.002_bib0025","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.002_bib0026","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2025-910","article-title":"Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK inhibitor\u2013naive myelofibrosis: 96-week results from the phase III MANIFEST-2 study","volume":"146","author":"Rampal","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.04.002_bib0027","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/bloodadvances.2020002177","article-title":"Development of luspatercept to treat ineffective erythropoiesis","volume":"5","author":"Kubasch","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2026.04.002_bib0028","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"10399","key":"10.1016\/j.clml.2026.04.002_bib0029","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.clml.2026.04.002_bib0030","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/bloodadvances.2024012939","article-title":"Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis","volume":"8","author":"Gerds","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.04.002_bib0031","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41375-021-01483-z","article-title":"Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms","volume":"36","author":"Balasubramanian","year":"2022","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.clml.2026.04.002_bib0032","doi-asserted-by":"crossref","first-page":"16581","DOI":"10.18632\/oncotarget.7667","article-title":"Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma","volume":"7","author":"Nakayama","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.clml.2026.04.002_bib0033","first-page":"1","article-title":"The selective inhibitor of nuclear export compound, selinexor, inhibits NF-\u03bab and induces anti-non-small cell lung cancer activity regardless of p53 status","volume":"2","author":"Crochiere","year":"2016","journal-title":"Int J Cancer Res Mol Mech"},{"key":"10.1016\/j.clml.2026.04.002_bib0034","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2023-186674","article-title":"Use of combination therapies including the XPO1 inhibitor selinexor in is a potential effective therapeutic strategy to treat myelofibrosis patients","volume":"142","author":"Lu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.002_bib0035","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1182\/blood-2023-180134","article-title":"Activity of Selinexor as a single agent and synergistic activity with approved\/investigational myelofibrosis therapies in vitro","volume":"142","author":"Maloof","year":"2023","journal-title":"Blood"},{"issue":"8_Supplement","key":"10.1016\/j.clml.2026.04.002_bib0036","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT261","article-title":"Abstract CT261: a phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-na\u00efve myelofibrosis","volume":"83","author":"Ali","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2026.04.002_bib0037","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1016\/S2152-2650(24)01443-5","article-title":"MPN-527 selinexor and ruxolitinib impact on symptom burden in patients with myelofibrosis is potentially driven by inhibition of NF-\u03bab and activation of P53 pathways","volume":"24","author":"Tantravahi","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.002_bib0038","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood-2023-180844","article-title":"Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-na\u00efve patients with myelofibrosis: long term follow up from XPORT-MF-034 suggestive of disease modification","volume":"142","author":"Tantravahi","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.04.002_bib0039","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.leukres.2010.07.042","article-title":"Dynamics of telomere\u2019s length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms","volume":"35","author":"Spanoudakis","year":"2011","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.clml.2026.04.002_bib0040","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.04.002_bib0041","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-138818","article-title":"Potential disease-modifying activity of imetelstat demonstrated by reduction in cytogenetically abnormal clones and mutation burden leads to clinical benefits in relapsed\/refractory myelofibrosis patients","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.04.002_bib0042","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1200\/JCO.2025.43.16_suppl.6515","article-title":"IMproveMF update: phase 1\/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF)","volume":"43","author":"Mascarenhas","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.002_bib0043","first-page":"65","article-title":"KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2I), for myelofibrosis (MF) relapsed or refractory (R\/R) to janus-associated kinase inhibitor (JAKI) treatment (TX)","volume":"4","author":"Al-Ali","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2026.04.002_bib0044","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1182\/blood-2024-201642","article-title":"Results from the randomized, multicenter, global phase 3 BOREAS study: navtemadlin versus best available therapy in JAK inhibitor relapsed\/refractory myelofibrosis","volume":"144","author":"Mascarenhas","year":"2024","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clml.2026.04.002_bib0045","article-title":"S210: an open-label, global, phase (Ph) 1b\/2 study adding navtemadlin (Nvtm) to ruxolitinib (Rux) in patients (pts) with primary or secondary myelofibrosis (MF) who have a suboptimal response to Rux","volume":"7","author":"Mascarenhas","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.clml.2026.04.002_bib0046","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3892\/br.2015.561","article-title":"Pim-1 kinase as cancer drug target: an update","volume":"4","author":"Tursynbay","year":"2016","journal-title":"Biomed Rep"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.002_bib0047","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2024-200312","article-title":"Nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, showed durable clinical response and sustained hematological improvement in relapsed\/refractory myelofibrosis patients","volume":"144","author":"El Chaer","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.002_bib0048","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2018-99-119421","article-title":"The PIM kinase inhibitor TP-3654 in combination with ruxolitinib exhibits marked improvement of myelofibrosis in murine models","volume":"132","author":"Nath","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.002_bib0049","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1182\/blood-2024-200268","article-title":"A phase 1\/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis","volume":"144","author":"Mascarenhas","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.002_bib0050","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/blood-2025-482","article-title":"Preliminary data from the phase I\/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed\/refractory myelofibrosis","volume":"146","author":"Mascarenhas","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.002_bib0051","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2022-159435","article-title":"Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms (MPNs)","volume":"140","author":"Reis","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.002_bib0052","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood-2025-484","article-title":"Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): preliminary results from dose escalation of two global phase 1 studies","volume":"146","author":"Mascarenhas","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.002_bib0053","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1182\/blood-2025-5576","article-title":"Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States","volume":"146","author":"Gerds","year":"2025","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.04.002_bib0054","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:16:02Z","timestamp":1793607362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026001023"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}